GastrointestinalIn Clinical Trials

Uroguanylin (Dolcanatide)

Oral

Overview

Uroguanylin is a 16-amino acid endogenous peptide structurally related to guanylin that also activates guanylate cyclase-C receptors in the intestinal epithelium. It regulates fluid and electrolyte secretion in the gut and plays a role in satiety signaling and metabolic homeostasis.

Mechanism of Action

The synthetic analog dolcanatide has been developed to mimic uroguanylin's effects with enhanced stability and bioavailability. Like guanylin, uroguanylin increases cyclic GMP levels, promoting intestinal secretion and motility..

Research Summary & Key Findings

Dolcanatide has been evaluated in clinical trials for chronic constipation and constipation-predominant irritable bowel syndrome, demonstrating improved bowel function in early-phase studies. A phase 2 trial published in 2011 showed dose-dependent increases in bowel movement frequency and stool consistency. Further clinical development has been limited, and the agent has not achieved regulatory approval.

Clinical Status

In Clinical Trials

Uroguanylin (Dolcanatide) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Oral

Related Peptides in Gastrointestinal

Find a Provider

Find a verified provider who offers Uroguanylin (Dolcanatide) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Uroguanylin (Dolcanatide).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.